Agree(ADC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADC Agree

Market Closed 11-15 16:00:00 EST

75.97

+0.38

+0.50%

盘后75.97

+0.000.00%

19:57 EST

High76.39	Low74.97	Vol626.10K
Open75.72	D1 Closing75.59	Amplitude1.88%
Mkt Cap8.28B	Tradable Cap8.13B	Total Shares109.00M
T/O47.56M	T/O Rate0.59%	Tradable Shares107.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ADC","market":"US","secType":"STK","nameCN":"Agree","latestPrice":75.97,"timestamp":1731704400000,"preClose":75.59,"halted":0,"volume":626097,"hourTrading":{"tag":"盘后","latestPrice":75.97,"preClose":75.97,"latestTime":"19:57 EST","volume":55783,"amount":4237852.2999,"timestamp":1731718638968},"delay":0,"floatShares":107000000,"shares":109000000,"eps":1.809026,"marketStatus":"Market Closed","change":0.38,"latestTime":"11-15 16:00:00 EST","open":75.72,"high":76.39,"low":74.97,"amount":47563111.50108,"amplitude":0.018786,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.809026,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1731920400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":766296000000,"exchange":"NYSE","adjPreClose":75.59,"dividendRate":0.039252,"preHourTrading":{"tag":"盘前","latestPrice":75.74,"preClose":75.59,"latestTime":"09:14 EST","volume":537,"amount":40339.142502,"timestamp":1731680085440},"postHourTrading":{"tag":"盘后","latestPrice":75.97,"preClose":75.97,"latestTime":"19:57 EST","volume":55783,"amount":4237852.2999,"timestamp":1731718638968},"volumeRatio":0.7463561763900368,"impliedVol":0.2085,"impliedVolPercentile":0.4048},"requestUrl":"/m/hq/s/ADC/wiki","defaultTab":"wiki","newsList":[{"id":"2483535280","title":"Mynaric Secures USD 11 Million Bridge Loan and Expects to Agree on an up to USD 9 Million Production Increase Incentive Agreement to Meet Immediate Working Capital Needs","url":"https://stock-news.laohu8.com/highlight/detail?id=2483535280","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483535280?lang=en_us&edition=fundamental","pubTime":"2024-11-16 05:30","pubTimestamp":1731706200,"startTime":"0","endTime":"0","summary":"MUNICH, GERMANY / ACCESSWIRE / November 15, 2024 / Mynaric AG   today entered into an amendment to its existing loan agreement with its U.S.-based lenders, which are funds affiliated with a U.S.-based global investment management firm, pursuant to which such lenders have agreed to provide a bridge loan in the amount of USD 11 million. Such bridge loan is in addition to the USD 95 million originally provided under such loan agreement and an initial bridge loan in the amount of USD 5.5 million that such lenders agreed to provide on October 2, 2024.In addition, the maturity date of the initial USD 5.5 million bridge loan is being extended and will now also be December 30, 2024.Excluding the USD 11 million related to the additional loan commitment and the initial USD 4.3 million payment from the production increase incentive agreement, as of November 15, 2024, the Company had cash and cash equivalents on hand of EUR 3.8 million, which the Company will also use to","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/AcImg1eSrHPhtgbVmN0W1Q--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/86281ed9803a2a26d2e0d1bedbe7c0cd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/AcImg1eSrHPhtgbVmN0W1Q--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/86281ed9803a2a26d2e0d1bedbe7c0cd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mynaric-secures-usd-11-million-213000965.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADC","MYNA","BK4080","BK4187","BK4231","USD","SOFR"],"gpt_icon":0},{"id":"2483077913","title":"Fidelity And Ex-Advisor Agree to End Lawsuit Over High-Fee Investments -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2483077913","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483077913?lang=en_us&edition=fundamental","pubTime":"2024-11-16 01:24","pubTimestamp":1731691440,"startTime":"0","endTime":"0","summary":"Fidelity Investments and a former financial advisor, who accused the company of improperly firing him for raising concerns about pressure to put clients in high-fee investment products that generated more revenue for Fidelity, have agreed to end their legal dispute.Fidelity and Michael Maeker jointly agreed this month to dismiss his case, according to court documents. A representative for Fidelity and Maeker's attorney, Rogge Dunn, both said in separate statements that \"the parties resolved their differences.\". Fidelity is one of the nation's largest asset and wealth management companies, and serves tens of millions of retail investors. The company had more than $15 trillion in assets as of Sept. 30.Fidelity terminated him in December 2022 for allegedly misrepresenting interactions with clients and improperly using planning tools, according to a note contained on his BrokerCheck record. Maeker disputed the allegations. He has no client complaints listed on BrokerCheck and his job perfo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","BK4231","BK4080"],"gpt_icon":0},{"id":"2483377900","title":"Press Release: OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483377900","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483377900?lang=en_us&edition=fundamental","pubTime":"2024-11-15 22:47","pubTimestamp":1731682020,"startTime":"0","endTime":"0","summary":"Topline Data from Phase 2b clinical trial of OST-HER2 in Osteosarcoma. OS Therapies, Inc.  , a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported financial results for the third quarter of 2024 ended September 30, 2024 and provided a business update.\"The third quarter was pivotal for OS Therapies as we completed our initial public offering and finished dosing the final patient enrolled in our Phase 2b clinical trial of OST-HER2 in resected, recurrent osteosarcoma,\" said Paul Romness, MHP, Chairman & CEO of OS Therapies. \"We are now looking forward to releasing topline data in December and then engaging with the FDA regarding getting this potentially life-saving cancer immunotherapy to patients that have no other potential treatment options as quickly as possible.\"","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","OS","BK4232","BK4139","R","BK4080","BK4231","BK4097","BK4022","ADC"],"gpt_icon":0},{"id":"2483388506","title":"UBS Adjusts Price Target on Agree Realty to $79 From $77, Maintains Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2483388506","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483388506?lang=en_us&edition=fundamental","pubTime":"2024-11-14 23:39","pubTimestamp":1731598782,"startTime":"0","endTime":"0","summary":"Agree Realty (ADC) has an average outperform rating and a price target range of $71 to $89, according to analysts polled by Capital IQ.(MT Newswires covers equity, commodity and economic research from","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADC"],"gpt_icon":0},{"id":"2483808976","title":"TransAlta, Energy Capital Partners Agree to Lower Heartland Acquisition Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2483808976","media":"MT Newswires Live","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483808976?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:29","pubTimestamp":1731590948,"startTime":"0","endTime":"0","summary":"TransAlta (TAC) said Thursday it has amended its share purchase agreement with Energy Capital Partners to lower the purchase price for Heartland Generation and Alberta Power by 80 million Canadian dol","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4231","ADC","TAC","BK4022","BK4232","HTLD","BK4080","BK4105"],"gpt_icon":0},{"id":"2483877262","title":"ArriVent BioPharma Reports Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483877262","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483877262?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:00","pubTimestamp":1731589200,"startTime":"0","endTime":"0","summary":"Robust firmonertinib monotherapy activity in front-line EGFR PACC mutant NSCLC including in patients with brain metastases Top-line pivotal data from global Phase 3 FURVENT trial for firmonertinib in ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/14/2981135/0/en/ArriVent-BioPharma-Reports-Third-Quarter-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","PACC","ADC","BK4080","CNS","BK4231","BK4135"],"gpt_icon":0},{"id":"2483777818","title":"PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483777818","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483777818?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:00","pubTimestamp":1731589200,"startTime":"0","endTime":"0","summary":"Conference call and webcast today at 8:30 a.m. Eastern TimePRINCETON, N.J., Nov.  14, 2024  (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-st","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/14/2981136/37149/en/PDS-Biotech-Provides-Clinical-Programs-Update-and-Reports-Third-Quarter-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PDS","ADC","BK4080","BK4092","BK4231"],"gpt_icon":0},{"id":"2483790228","title":"Tapestry, Capri Agree to Terminate Merger Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2483790228","media":"MT Newswires Live","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483790228?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:17","pubTimestamp":1731586677,"startTime":"0","endTime":"0","summary":"Tapestry  said Thursday it has agreed with Capri Holdings  to terminate their merger agreement amid regulator opposition to the deal.The high-end apparel and accessories retailer said the legal process surrounding the merger is uncertain and unlikely to be resolved by Feb. 10.Chief Executive Joanne Crevoiserat said the company will find organic ways to accelerate growth.The company also announced an additional $2 billion share repurchase authorization, adding to an existing $800 million outstanding on a prior authorization.The company said it will redeem $6.1 billion in senior notes associated with the planned acquisition and has agreed to reimburse Capri's transaction expenses of approximately $45 million.The company also said it is reaffirming its fiscal 2025 outlook.Tapestry's shares were up more than 3% while Capri's shares were down 5% in recent Thursday premarket activity.Price: 53.25, Change: +1.99, Percent Change: +3.88","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4080","BK4516","TPR","LU0208291251.USD","BK4231","LU0070302665.USD","BK4585","CPRI","BK4588","LU0310800965.SGD","LU0052756011.USD","BK4202","LU0320765489.SGD","LU0128525689.USD","ADC","LU1267930227.SGD"],"gpt_icon":0},{"id":"2483875209","title":"Agree Realty Corp : Mizuho Raises Target Price to $80 From $75","url":"https://stock-news.laohu8.com/highlight/detail?id=2483875209","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483875209?lang=en_us&edition=fundamental","pubTime":"2024-11-14 19:58","pubTimestamp":1731585509,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nFWN3ML0WF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4080","BK4231","ADC"],"gpt_icon":0},{"id":"2483875182","title":"Tapestry, Capri Holdings Agree to Terminate Merger Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2483875182","media":"MT Newswires Live","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483875182?lang=en_us&edition=fundamental","pubTime":"2024-11-14 19:53","pubTimestamp":1731585222,"startTime":"0","endTime":"0","summary":"Price: 50.52, Change: -0.74, Percent Change: -1.44","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0052756011.USD","LU0070302665.USD","BK4231","BK4080","BK4202","CPRI","LU0320765489.SGD","LU0128525689.USD","LU0208291251.USD","TPR","LU0310800965.SGD","BK4516","LU1267930227.SGD","BK4585","ADC","BK4588"],"gpt_icon":0},{"id":"2483980118","title":"Agree Realty price target raised to $80 from $75 at Mizuho","url":"https://stock-news.laohu8.com/highlight/detail?id=2483980118","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483980118?lang=en_us&edition=fundamental","pubTime":"2024-11-14 09:40","pubTimestamp":1731548415,"startTime":"0","endTime":"0","summary":"Mizuho raised the firm’s price target on Agree Realty (ADC) to $80 from $75 and keeps a Neutral rating on the shares as part of a broader research ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/agree-realty-price-target-raised-to-80-from-75-at-mizuho?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/agree-realty-price-target-raised-to-80-from-75-at-mizuho?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADC","MFG"],"gpt_icon":0},{"id":"2483486546","title":"Two of Blue Owl Capital's Funds Agree to Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2483486546","media":"Dow Jones","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483486546?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:55","pubTimestamp":1731534900,"startTime":"0","endTime":"0","summary":"Blue Owl Technology Finance Corp. and Blue Owl Technology Finance Corp. II have agreed to a merger.The combination of these two complementary portfolios will allow for portfolio consolidation and mitigate potential integration risk, said Blue Owl Capital, which constructed and manages the funds.OTF will be the surviving company. Under the terms of the merger, shareholders of OTF II will receive a number of shares of OTF common stock with a net asset value equal to the net asset value of shares of OTF II common stock that they hold at the time of closing, the New York asset management firm said Wednesday.The transaction is expected to close in the second quarter of 2025, subject to certain conditions.Both funds employ the same investment strategy, according to Blue Owl. At the end of the third quarter, approximately 84% of the investments in OTF II overlapped with those of OTF.The merger is set to increase OFT's scale and diversity, enhance its positioning for a possible future liquidit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OWL","BK4231","ADC","IE00BLSP4452.SGD","IE00BBT3K403.USD","BK4135","BK4080","IE00BLSP4239.USD"],"gpt_icon":0},{"id":"2483830100","title":"Pitney Bowes, DRF Logistics Agree in Principle to Resolve Outstanding Disputes With Unsecured Creditors in Bankruptcy Case","url":"https://stock-news.laohu8.com/highlight/detail?id=2483830100","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483830100?lang=en_us&edition=fundamental","pubTime":"2024-11-13 22:32","pubTimestamp":1731508369,"startTime":"0","endTime":"0","summary":"Pitney Bowes  said Wednesday it reached an agreement in principle with its former global e-commerce unit, DRF Logistics, to resolve ongoing disputes with an official committee of unsecured creditors.Pitney Bowes said it expects the resolution to help keep DRF's exit on track to completion by the end of the year. It is also targeting $150 million in one-time costs from the wind down.Price: 7.87, Change: +0.29, Percent Change: +3.83","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4231","ADC","BK4143","BK4080","PBI","BK6039","NEX.SI","BK4547","BK6520"],"gpt_icon":0},{"id":"2483889546","title":"$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2483889546","media":"Business Wire","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483889546?lang=en_us&edition=fundamental","pubTime":"2024-11-13 22:00","pubTimestamp":1731506400,"startTime":"0","endTime":"0","summary":"Innovative Antibodies Show Promise for Antibody-Drug Conjugate  Development, Paving the Way for Transformative Cancer Treatments. TrkB is a protein commonly found in aggressive cancers. IPA is spearheading two programs that target this protein. The TATX-200 program is centered on developing T cell engagers, which boost the body's immune response against tumors. The TATX-112 program is focused on creating antibodies that can deliver cancer-killing drugs directly to tumor cells. The recent advancements in the TATX-112 program have led to the discovery of multiple antibodies that can infiltrate and eliminate TrkB-expressing cells in an in vitro surrogate Antibody Drug Conjugate  assay. This suggests that these antibodies could be used to deliver drugs directly to cancer cells, potentially enhancing the effectiveness and safety of cancer treatments targeting TrkB.ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.F7Hbu3oT8R6xfpEYMIHyg--~B/aD0zMzk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/d84d9c6d716a215d7582155a31ebbc4d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.F7Hbu3oT8R6xfpEYMIHyg--~B/aD0zMzk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/d84d9c6d716a215d7582155a31ebbc4d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/20-billion-market-breakthrough-ipa-140000451.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADC","BK4080","BK4121","BK4231","IPA"],"gpt_icon":1},{"id":"2483006307","title":"Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2483006307","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483006307?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:00","pubTimestamp":1731499200,"startTime":"0","endTime":"0","summary":"Proposed merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing  Journey’s next-gen, first-in-class ADC-rivalling, nano-immunoconjugates  platform and therapeutic products for unmet medical needs in oncology and autoimmune diseases and  Entero’s gastrointestinal product pipeline for treating unmet metabolic and rare genetic diseases;The NIC platform technology is invented by and originated from Svetomir N. Markovic, M.D., Ph.D. of Mayo Clinic and is exclusively licensed by Journey with worldwide rights to sublicense;NIC Platform is being applied to multiple cancer indications, including difficult to treat end-stage gynecologic tumors and lymphoma with limited responses or resistant to existing therapies;Early-stage clinical results of various NIC products are well-published and further developments are expected in the near-term; and. Following the completion of the Proposed Merger, the new entity would be under the leadership of Henry Ji, Ph.D., C","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YmGJTEOE07RYJkXed5miDg--~B/aD0yODY7dz00NTM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/85ae258b328d347dbafd6e7b5c592879","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YmGJTEOE07RYJkXed5miDg--~B/aD0yODY7dz00NTM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/85ae258b328d347dbafd6e7b5c592879"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/entero-therapeutics-announces-proposed-reverse-120000996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","ENTO","BK4080","LENZ","BK4139","NIC","SSI","BK4211","BK4181","BK4231","PK","ADC"],"gpt_icon":0},{"id":"2483032270","title":"BioNTech to Acquire Biotheus to Boost Oncology Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2483032270","media":"GlobeNewswire","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483032270?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:45","pubTimestamp":1731498300,"startTime":"0","endTime":"0","summary":"Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential to re","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/13/2980068/0/en/BioNTech-to-Acquire-Biotheus-to-Boost-Oncology-Strategy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","L","BK4588","BK4230","BK4107","CAR","BK4585","BK4080","ADC","LU0053666078.USD","BK4022"],"gpt_icon":0},{"id":"2483008436","title":"Azeris, Kazakhs, Uzbeks Agree to Develop, Export Clean Energy","url":"https://stock-news.laohu8.com/highlight/detail?id=2483008436","media":"Bloomberg","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483008436?lang=en_us&edition=fundamental","pubTime":"2024-11-13 18:19","pubTimestamp":1731493195,"startTime":"0","endTime":"0","summary":"Azerbaijan, Kazakhstan and Uzbekistan have signed an agreement to develop green energy and supply it to Europe via cables to be laid under the Caspian and Black seas.","market":"sg","thumbnail":"https://www.bnnbloomberg.ca/resizer/v2/3PF5EWQ2QQ2NFQJK2SZCJQ5DWM.jpg?smart=true&auth=18e5a6275dca9880713ad8a5d8d000e96c5aa0d2d096b68ccdbc361b5aaa3edf&width=500&height=333","type":0,"news_type":0,"thumbnails":["https://www.bnnbloomberg.ca/resizer/v2/3PF5EWQ2QQ2NFQJK2SZCJQ5DWM.jpg?smart=true&auth=18e5a6275dca9880713ad8a5d8d000e96c5aa0d2d096b68ccdbc361b5aaa3edf&width=500&height=333"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.bnnbloomberg.ca/investing/commodities/2024/11/13/azeris-kazakhs-uzbeks-agree-to-develop-export-clean-energy/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bnn_bloomberg_highlight","symbols":["BK4080","BK4231","ADC"],"gpt_icon":0},{"id":"2483726049","title":"Press Release: Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483726049","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483726049?lang=en_us&edition=fundamental","pubTime":"2024-11-13 14:00","pubTimestamp":1731477600,"startTime":"0","endTime":"0","summary":"Jonathan Dickinson appointed Chief Executive Officer and Chairman of. Encouraging initial FDA feedback received on lacutamab regulatory. Lacutamab health-related quality of life and translational data to be. IPH4502, a Nectin-4 ADC received FDA clearance of the IND to be. Preclinical data for proprietary tetra-specific NK cell engager IPH6501. Cash position of EUR96.4 million1 as of September 30, 2024, anticipated. Innate Pharma SA   today announced its business update and financial results for the first nine months of 2024.found on the Investors section of the Innate Pharma website,www.innate-pharma.com. A replay of the webcast will be available on the. TELLOMAK is a global, open-label, multi-cohort Phase 2 clinical trial evaluating lacutamab in patients with Sézary syndrome and mycosis fungoides.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPHA","BK4080","BK4022","R","BK4139","BK4109","SITC","BK4231","BK4232","ASH","LU2463526074.USD","CRT","IPHYF","BK4213","ADC"],"gpt_icon":0},{"id":"2483099181","title":"Helix BioPharma Highlights L-DOS47 at World ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=2483099181","media":"TIPRANKS","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483099181?lang=en_us&edition=fundamental","pubTime":"2024-11-13 08:40","pubTimestamp":1731458442,"startTime":"0","endTime":"0","summary":"Helix BioPharma (TSE:HBP) has released an update. Helix BioPharma Corp. showcased its innovative L-DOS47 platform at the World ADC San Diego, under...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/helix-biopharma-highlights-l-dos47-at-world-adc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/helix-biopharma-highlights-l-dos47-at-world-adc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADC","BK4080","BK4231"],"gpt_icon":0},{"id":"2483067741","title":"Agree Realty declares $0.253 dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2483067741","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483067741?lang=en_us&edition=fundamental","pubTime":"2024-11-13 06:39","pubTimestamp":1731451171,"startTime":"0","endTime":"0","summary":"Agree Realty (NYSE:ADC) declares $0.253/share monthly dividend, in line with previous.\n\nForward yield 3.98%\nPayable Dec. 13; for shareholders of record Nov. 29; ex-div Nov. 29.\nSee ADC Dividend Scorecard, Yield Chart, & Dividend Growth.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4282602-agree-realty-declares-0_253-dividend","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["US10Y.BOND","US12M.BOND","US6M.BOND","US2Y.BOND","US5Y.BOND","ADC","BK4080","US7Y.BOND","BK4231","US30Y.BOND","US3Y.BOND"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agreerealty.com","stockEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":-0.0094},{"period":"3month","weight":0.0643},{"period":"6month","weight":0.2551},{"period":"1year","weight":0.3044},{"period":"ytd","weight":0.2068}],"compareEarnings":[{"period":"1week","weight":-0.0208},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0567},{"period":"6month","weight":0.1063},{"period":"1year","weight":0.301},{"period":"ytd","weight":0.2324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Agree Realty Corporation (the Company), a Maryland corporation, is a fully integrated real estate investment trust (REIT) primarily focused on the ownership, acquisition, development and management of retail properties net leased to industry leading tenants. The Company was founded in 1971 by its current Executive Chairman, Richard Agree, and its common stock was listed on the New York Stock Exchange in 1994. As of March 31, 2024, the Company owned 2,161 properties, with a total gross leasable area (GLA) of approximately 44.9 million square feet.","yearOnYearQuotes":[{"month":1,"riseRate":0.566667,"avgChangeRate":-0.004913},{"month":2,"riseRate":0.433333,"avgChangeRate":-0.00204},{"month":3,"riseRate":0.566667,"avgChangeRate":0.014268},{"month":4,"riseRate":0.566667,"avgChangeRate":0.002707},{"month":5,"riseRate":0.516129,"avgChangeRate":0.017098},{"month":6,"riseRate":0.677419,"avgChangeRate":0.011409},{"month":7,"riseRate":0.677419,"avgChangeRate":0.024183},{"month":8,"riseRate":0.451613,"avgChangeRate":0.001804},{"month":9,"riseRate":0.483871,"avgChangeRate":-0.005771},{"month":10,"riseRate":0.548387,"avgChangeRate":-0.001244},{"month":11,"riseRate":0.645161,"avgChangeRate":0.002363},{"month":12,"riseRate":0.5,"avgChangeRate":0.014772}],"exchange":"NYSE","name":"Agree","nameEN":"Agree"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Agree(ADC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Agree(ADC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Agree,ADC,Agree股票,Agree股票老虎,Agree股票老虎国际,Agree行情,Agree股票行情,Agree股价,Agree股市,Agree股票价格,Agree股票交易,Agree股票购买,Agree股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Agree(ADC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Agree(ADC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction